{
  "html": "<table border=\"1px\" style=\"width: 100%;\"> <tbody><tr><td>&nbsp;</td>\n\t\t\t\t\t<th>PC Number</th>\n\t\t\t\t\t<th>Date</th>\n\t\t\t\t\t<th>Chapter</th>\n\t\t\t\t\t<th>Bill</th>\n\t\t\t\t\t<th>Dept</th></tr><tr><td style=\"min-width: 120px;\">&nbsp;</td><td>2017-1502</td><td>2017-12-01</td><td></td><td></td><td>TB,&nbsp; HC,&nbsp; ,&nbsp; ,&nbsp; ,&nbsp; </td></tr><tr><td>Act</td><td colspan=\"5\">Financial Administration Act</td></tr><tr><td>Subject</td><td colspan=\"5\">Regulations Amending the Fees in Respect of Drugs and Medical Devices Regulations (DIN Requirements for Drugs Listed in Schedule C to the Food and Drugs Act that are in Dosage Form)</td></tr><tr><td>Precis</td><td colspan=\"5\" id=\"precis\">Regulations Amending the FEES IN RESPECT OF DRUGS AND MEDICAL DEVICES REGULATIONS (DIN Requirements for Drugs Listed in Schedule C to the Food and Drugs Act that are in Dosage Form) in order to (1) remove the Drug Identification Number (DIN) exemption and clearly outline the labelling requirements for Schedule C drugs in order to align the DIN application process and labelling requirements for Schedule C drugs with all other drug products that have DINs; (2) require Schedule C drug manufacturers to notify Health Canada within 30 days of a product being marketed or discontinued; and (3) broaden the scope of the 12 months no sale notification to require manufacturers of all DIN products not covered under the shortage and discontinuation regulations, to notify Health Canada after a 12-month period of no sale as part of the annual notification process.</td></tr><tr><td>Registration</td><td colspan=\"5\" id=\"registration\"><strong>Registration: </strong>SOR/ 2017-0260  <strong>Publication Date:</strong> 2017-12-13</td></tr><tr><td>Attachments</td><td colspan=\"5\"><a href=\"attachment.php?attach=35413&amp;lang=en\">Attachment</a></td></tr></tbody></table>",
  "pcNumber": "2017-1502",
  "htmlHash": "ade5c79e5bb57fcd302ad48639c7da2f"
}